Kintai, Studying The Enteric Signaling Pathway, Is Looking For Partners
Executive Summary
Emerging Company Profile: The start-up, funded by Flagship Pioneering, is developing small molecules across multiple therapeutic areas, based on a discovery platform exploring the microbiome, gut immune system and enteric nervous system.
You may also be interested in...
Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.